Tactile Systems Technology (TCMD) Q2 2026 Earnings Call Transcript
Tactile Systems Technology (TCMD) reported Q2 2026 revenue of $85.7M, up 9% Y/Y, driven by lymphedema revenue of $73.6M (+12%). Airway clearance revenue fell 7% to $12.1M due to distributor inventory dynamics. Gross margin was 76.3%. Adjusted EBITDA rose to $11.4M (+49%). FY2026 revenue guidance was set at $360M-$366M and EBITDA at $49M-$51M.
How this was made
The 30-second read
Why it matters
The key tradable elements are the updated FY2026 revenue range, maintained adjusted EBITDA guidance, and the stated drivers of near-term variability: Medicare prior authorization moderation and airway-clearance distributor inventory dynamics.
Market read
Traders can reassess FY2026 revenue trajectory and segment timing risk (Medicare and distributor inventory) while monitoring whether management’s Q4 normalization comment is credible.
What to watch
R&D spend is rising (up 24% YoY) while R&D is tied to software and technology initiatives; execution risk around LymphaTech integration and 2027 FDA expansion could affect longer-term valuation.
Background
Tactile Systems Technology (TCMD) held its Q2 2026 earnings call, covering revenue by product line, margin/EBITDA performance, and updates to FY2026 guidance plus clinical and distribution milestones.
Ticker impact
TCMD reported Q2 revenue of $85.7M (+9% YoY) and updated FY2026 guidance to $360M-$366M amid airway-clearance inventory dynamics.
Likely choppy trading around guidance interpretation, with upside bias if Q4 normalization in airway clearance is credible.
The article provides concrete earnings and guidance numbers, but it is a transcript-style disclosure without explicit consensus surprise or a new regulatory decision.
Market effects
Reinforces demand sensitivity in DME and Medicare-administered ordering flows, with reimbursement process changes affecting near-term volumes.
Primarily US Medicare and DoD/VA channel dynamics.
Limited, as the disclosed catalysts are US reimbursement and US distribution agreements.
Counterpoint
Airway-clearance weakness may be more than temporary inventory management, and Medicare prior authorization effects could persist longer than management expects.
Key entities
- companyTactile Systems Technology, Inc.
Reported Q2 results and updated FY2026 guidance; discussed Medicare prior authorization impact, airway-clearance inventory dynamics, and upcoming FDA/clinical milestones.
- executiveSheri Dodd
CEO who attributed near-term moderation to April 13 Medicare prior authorization and discussed clinical and regulatory plans.
- executiveElaine Birkemeyer
CFO who discussed segment headwinds and normalization expectations for airway-clearance purchasing activity.
